EU4

OSE-2101 (Tedopi) for Ovarian Cancer in 7MM: Market Size, Forecasts, and Emerging Insights 2019-2023 & 2024-2032 - ResearchAndMarkets.com

Retrieved on: 
金曜日, 5月 17, 2024
Pharmaceutical, Health, Oncology, Patient, SWOT, Ovarian cancer, Clinical trial, Research, EU4, Mobile phone

"OSE-2101 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about OSE-2101 for ovarian cancer in the seven major markets.

Key Points: 
  • "OSE-2101 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about OSE-2101 for ovarian cancer in the seven major markets.
  • Further, it also consists of future market assessments inclusive of the OSE-2101 market forecast analysis for ovarian cancer in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ovarian cancer.
  • Other emerging products for ovarian cancer are expected to give tough market competition to OSE-2101 and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • What are the other emerging products available and how are these giving competition to OSE-2101 for ovarian cancer?

ASC22 (Envafolimab) for Chronic Hepatitis B in 7MM: Market Size, Forecasts, and Emerging Insights 2019-2023 & 2024-2032 - ResearchAndMarkets.com

Retrieved on: 
金曜日, 5月 17, 2024
Health, Pharmaceutical, HBsAg, Patient, SWOT, Nas, Conditional sentence, Clinical trial, Safety, Research, CHB, Hepatitis, PD-L1, Quality of life, Temperature, EU4, Vaccine

"ASC22 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about ASC22 for chronic hepatitis B in the seven major markets and China.

Key Points: 
  • "ASC22 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about ASC22 for chronic hepatitis B in the seven major markets and China.
  • Further, it also consists of future market assessments inclusive of the ASC22 market forecast analysis for chronic hepatitis B in the 7MM and China, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in chronic hepatitis B.
    ASC22, also known as envafolimab, is a first-in-class, subcutaneously administered PD-L1 antibody for chronic hepatitis B (CHB) functional cure.
  • Other emerging products for chronic hepatitis B are expected to give tough market competition to ASC22 and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • What are the other emerging products available and how are these giving competition to ASC22 for chronic hepatitis B?

JNJ-73763989 (JNJ-6379) for Chronic Hepatitis B in 6MM: Market Size, Forecasts, and Emerging Insight 2019-2023 & 2024-2032 - ResearchAndMarkets.com

Retrieved on: 
金曜日, 5月 17, 2024
Infectious Diseases, Pharmaceutical, Health, Clinical Trials, CccDNA, Patient, DNA, SWOT, Clinical trial, Arrowhead Pharmaceuticals, HBV, Janssen Pharmaceuticals, DDI, Research, Hepatitis, RNA interference, EU4, Vaccine

"JNJ-73763989 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about JNJ-73763989 for chronic hepatitis B in the six major markets.

Key Points: 
  • "JNJ-73763989 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about JNJ-73763989 for chronic hepatitis B in the six major markets.
  • Other emerging products for chronic hepatitis B are expected to give tough market competition to JNJ-73763989 and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • What are the other emerging products available and how are these giving competition to JNJ-73763989 for chronic hepatitis B?
  • Which are the late-stage emerging therapies under development for the treatment of chronic hepatitis B?

KEYTRUDA for Ovarian cancer in 7MM: Market Assessment, Competitive Landscape, Forecasts, and Emerging Insights 2019-2032 - ResearchAndMarkets.com

Retrieved on: 
金曜日, 4月 26, 2024
Biotechnology, Health, Oncology, FDA, Safety, SWOT, Carcinoma, EU4, Research, PD-1, Hodgkin lymphoma, Melanoma, Clinical trial, Peripheral tolerance, Cancer, Ovarian cancer, Lung cancer, Pharmaceutical industry

The report provides comprehensive insights about KEYTRUDA for ovarian cancer in the seven major markets.

Key Points: 
  • The report provides comprehensive insights about KEYTRUDA for ovarian cancer in the seven major markets.
  • Further, it also consists of future market assessments inclusive of the KEYTRUDA market forecast analysis for ovarian cancer in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ovarian cancer.
  • Other emerging products for ovarian cancer are expected to give tough market competition to KEYTRUDA and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • What are the other emerging products available and how are these giving competition to KEYTRUDA for ovarian cancer?

mRNA-1345 for Respiratory Syncytial Virus (RSV) in 7MM: Market Size, Forecasts, and Emerging Insights 2019-2032 - ResearchAndMarkets.com

Retrieved on: 
木曜日, 4月 25, 2024
Biotechnology, Pharmaceutical, Health, Protein, SWOT, EU4, RNA, Research, DSMB, Messenger, Immune system, RSV, Vaccine

"mRNA-1345 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about mRNA-1345 for Respiratory syncytial virus (RSV) in the seven major markets.

Key Points: 
  • "mRNA-1345 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about mRNA-1345 for Respiratory syncytial virus (RSV) in the seven major markets.
  • The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities.
  • Further, it also consists of future market assessments inclusive of the mRNA-1345 market forecast analysis for RSV in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in RSV.
  • The mRNA-1345 RSV vaccine candidate prevents illness from RSV, a leading cause of respiratory illness in young and older adults (65+).

Nemvaleukin Alfa (Previously known as ALKS 4230) Drug Landscape Report 2024: An Interleukin-2 Receptor Agonist for the Treatment of Solid Tumors - Size, Forecasts, and Insights 2019-2032 - ResearchAndMarkets.com

Retrieved on: 
木曜日, 4月 18, 2024
Pharmaceutical, Health, Oncology, Fallopian tube cancer, SWOT, EU4, Research, Carcinoma, ALKS, Alkermes, Head, Clinical trial, Ovarian cancer, Birth control

"Nemvaleukin alfa Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about nemvaleukin alfa for ovarian cancer in the seven major markets.

Key Points: 
  • "Nemvaleukin alfa Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about nemvaleukin alfa for ovarian cancer in the seven major markets.
  • Nemvaleukin alfa (previously known as ALKS 4230) is an interleukin-2 receptor agonist being developed by Alkermes for the treatment of solid tumors, including head and neck cancer, small cell lung cancer, ovarian cancer, fallopian tube cancer, and others.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of nemvaleukin alfa in ovarian cancer.
  • What are the other emerging products available and how are these giving competition to nemvaleukin alfa for ovarian cancer?

GSK3528869A (Bepirovirsen) for Chronic Hepatitis B Drug Pipeline Research 2024: Market Size, Forecast, and Emerging Insights 2019-2032 - ResearchAndMarkets.com

Retrieved on: 
木曜日, 4月 18, 2024
Research, Infectious Diseases, Chemicals, Plastics, Clinical Trials, Manufacturing, Biotechnology, Pharmaceutical, Health, Science, Other Science, Hepatocyte, Protein, SWOT, Hepatitis, TLR8, EU4, Group C, RNA, Toll-like receptor 8, Disease, MPL, GSK, Hepatitis B virus, HBcAg, Immune system, Clinical trial, HBV, Vaccine

The report provides comprehensive insights about GSK3528869A Bepirovirsen for chronic hepatitis B in the seven major markets and China.

Key Points: 
  • The report provides comprehensive insights about GSK3528869A Bepirovirsen for chronic hepatitis B in the seven major markets and China.
  • Other emerging products for chronic hepatitis B are expected to give tough market competition to GSK3528869A Bepirovirsen and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of GSK3528869A Bepirovirsen in chronic hepatitis B.
  • What are the other emerging products available and how are these giving competition to GSK3528869A Bepirovirsen for chronic hepatitis B?

OPDIVO (Nivolumab) Drug Pipeline Research Report 2024: The First-in-human Immunoglobulin G4 (IgG4) PD-1 Immune Checkpoint Inhibitor Antibody - Market Size, Forecast, and Emerging Insights 2019-2032 - ResearchAndMarkets.com

Retrieved on: 
木曜日, 4月 18, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, PD-L2, SWOT, Ligand, EU4, Trial of the century, PD-1, Fibroadenoma, PD-L1, Immunoglobulin G, Patient, Neoplasm, Clinical trial, Ovarian cancer, Birth control

This report provides comprehensive insights about OPDIVO for ovarian cancer in the six major markets.

Key Points: 
  • This report provides comprehensive insights about OPDIVO for ovarian cancer in the six major markets.
  • The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities.
  • OPDIVO (also known as Nivolumab) is the first-in-human immunoglobulin G4 (IgG4) PD-1 immune checkpoint inhibitor antibody that disrupts the interaction of the PD-1 receptor with its ligands PD-L1 and PD-L2, thereby inhibiting the cellular immune response.
  • What are the other emerging products available and how are these giving competition to OPDIVO for ovarian cancer?

Alport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsight

Retrieved on: 
水曜日, 4月 17, 2024
USD, Urine, ACE, Finerenone, ESRD, Kidney, Otorhinolaryngology, Nephrotoxicity, Mutation, Hearing, Diagnosis, Glomerular filtration rate, Hearing loss, Blood, Swelling, Proteinuria, Kidney failure, Cochlea, Alport syndrome, Nephrology, EU4, GFR, ADAS, Heredity, Research, Genetic counseling, Kidney disease, Novartis, ARAS, Ophthalmology, COL4A4, Patient, Kidney transplantation, LAS, Dialysis, DSM-IV codes, COL4A3, Quality of life, Genetic disorder, Gene, Pharmaceutical industry

LAS VEGAS, April 17, 2024 /PRNewswire/ -- DelveInsight's Alport Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Alport syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Key Points: 
  • Leading Alport syndrome companies such as Eloxx Pharmaceuticals, Chinook Therapeutics (A Novartis company), Bayer, Calliditas Therapeutics, Evotec, and others are developing novel Alport syndrome drugs that can be available in the Alport syndrome market in the coming years.
  • The disorder manifests in different forms such as autosomal recessive Alport syndrome (ARAS), X-linked Alport syndrome (XLAS), and autosomal dominant Alport syndrome (ADAS).
  • The X-linked Alport syndrome (XLAS) is the most prevalent subtype of Alport syndrome with around 11K cases in 2023 in the US while autosomal dominant Alport syndrome (ADAS) is the least prevalent subtype of Alport syndrome.
  • To know more about Alport syndrome treatment guidelines, visit @ Alport Syndrome Management

Alport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsight

Retrieved on: 
水曜日, 4月 17, 2024
USD, Urine, ACE, Finerenone, ESRD, Kidney, Otorhinolaryngology, Nephrotoxicity, Mutation, Hearing, Diagnosis, Glomerular filtration rate, Hearing loss, Blood, Swelling, Proteinuria, Kidney failure, Cochlea, Alport syndrome, Nephrology, EU4, GFR, ADAS, Heredity, Research, Genetic counseling, Kidney disease, Novartis, ARAS, Ophthalmology, COL4A4, Patient, Kidney transplantation, LAS, Dialysis, DSM-IV codes, COL4A3, Quality of life, Genetic disorder, Gene, Pharmaceutical industry

LAS VEGAS, April 17, 2024 /PRNewswire/ -- DelveInsight's Alport Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Alport syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Key Points: 
  • Leading Alport syndrome companies such as Eloxx Pharmaceuticals, Chinook Therapeutics (A Novartis company), Bayer, Calliditas Therapeutics, Evotec, and others are developing novel Alport syndrome drugs that can be available in the Alport syndrome market in the coming years.
  • The disorder manifests in different forms such as autosomal recessive Alport syndrome (ARAS), X-linked Alport syndrome (XLAS), and autosomal dominant Alport syndrome (ADAS).
  • The X-linked Alport syndrome (XLAS) is the most prevalent subtype of Alport syndrome with around 11K cases in 2023 in the US while autosomal dominant Alport syndrome (ADAS) is the least prevalent subtype of Alport syndrome.
  • To know more about Alport syndrome treatment guidelines, visit @ Alport Syndrome Management